Key facts
- This page summarizes Na Yeon Kim's Form 4 filing for NeuroBo Pharmaceuticals, Inc. (MTVA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jul 2023, 06:08.
Na Yeon Kim - 27 Jul 2023 Form 4 Insider Report for NeuroBo Pharmaceuticals, Inc. (MTVA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- MTVA
- Reported as of
- 27 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jul 2023, 06:08:20 UTC
- Prior SEC filing
- 28 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Phillip D. Torrence, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Na Yeon Kim filed Form 4 for NeuroBo Pharmaceuticals, Inc. (MTVA) on 28 Jul 2023.
Change
- Previous filing in this sequence was filed on 28 Jul 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NRBO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +87,500
- Change %
- +5997%
- Price
- $0.000000
- Shares after
- 88,959
- Date
- 27 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
NRBO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 101,459
- Date
- 27 Jul 2023
- Ownership
- Direct
- Footnotes
- F1, F4
NRBO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,671
- Date
- 27 Jul 2023
- Ownership
- Held by E&Investment Inc.
- Footnotes
- F5
NRBO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 96,351
- Date
- 27 Jul 2023
- Ownership
- Held by The E&Healthcare Investment Fund II
- Footnotes
- F3, F5
NRBO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 37,373
- Date
- 27 Jul 2023
- Ownership
- Held by The E&Healthcare Investment Fund No. 6
- Footnotes
- F3, F5
NRBO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 62,159
- Date
- 27 Jul 2023
- Ownership
- Held by The E&Healthcare Investment Fund No. 7
- Footnotes
- F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.
Footnote F2
50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.
Footnote F3
The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
Footnote F4
Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
Footnote F5
Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.